Previous Webinar

Milka Kostic, PhD, is the Chemical Biology Program Director of the Dana-Farber Cancer Institute. She is responsible for the strategic framework and support for a unique chemical biology program for advancing basic science of cancer chemical biology and addressing challenging targets for cancer treatments. Prior to Dana-Farber, Milka was the Editor of “Cell Chemical Biology” and “Structure” for more than a decade. Throughout her career, Milka is a strong supporter of chemical biology and structural biology as a scientist, editor or program director.

Cheryl Arrowsmith is the Chief Scientist of the Toronto Node of the Structural Genomics Consortium (SGC), a multinational public-private partnership that supports the discovery of new medicines through protein-based open access research. She leads the SGC’s program to develop chemical probes to chromatin regulators for target validation. Cheryl is also Sr. Scientist at Princess Margaret Cancer Centre in Toronto. Her current research interests focus on structural and chemical biology of chromatin and epigenetic regulatory factors especially as relates to cancer.

Thomas Landrain is co-founder of the non-profit Just One Giant Lab online platform (JOGL.io), a community-based open research institute to support open science projects and communities around the world. He has a PhD in synthetic biology, co-founded the first French iGEM team in 2007, and co-founded the biotech company PILI in 2015. Thomas designs, experiment on and implement systems to make science and innovation more open and inclusive.

Professor Paul Workman FRS FMedSci FRSC is a multidisciplinary cancer research scientist, molecular pharmacologist and chemical biologist who has been responsible for the laboratory discovery of chemical probes and innovative cancer drugs. His specialty is designing personalized cancer medicines that are targeted to precise molecular abnormalities and vulnerabilities – an approach he refers to as ‘drugging the cancer genome’. Paul is particularly well known for the discovery of clinical drug candidates and chemical probes inhibiting protein kinases, PI3 kinases, the molecular chaperone HSP90 and recently the HSF1 pathway.

Albert Antolin is an ICR Fellow and Junior Team Leader in the Department of Data Science and Division of Cancer Therapeutics at the ICR. His research focuses on computational chemical biology methods and resources applied to translational cancer research and drug discovery. In addition, he serves as the Associate Director of Chemoinformatics at the non-profit Chemical Probes Portal to promote the use of high-quality chemical probes and increase the robustness and reproducibility of biomedical research.

Ctibor Skuta is Postdoctoral Fellow at CZ-OPENSCREEN, National Infrastructure for Chemical Biology at the Institute of Molecular Genetics of the Czech Academy of Sciences. He is closely associated with the Probes & Drugs portal, a hub for the integration of high-quality bioactive compound sets enabling their analysis and comparison. Together with colleagues, he recently published a comprehensive and comparative overview of chemical probe sources, structures and targets.

Christopher Southan is a Competitive Intelligence Analyst at Medicines Discovery Catapult (MDC). Prior to this he operated TW2Informatics Consulting 2019-21. Before this he was a member of the IUPHAR/BPS Guide to Pharmacology database team from 2012-18. He is also a member of the Chemical Probes Portal Scientific Expert Review Panel. Recent publications include " Will the chemical probes please stand up?" PMID:34447939 and"The IUPHAR/BPS Guide to Pharmacology in 2022" PMID:34718737 (further details on LinkedIN).

Florian Montel is Senior Principal Scientist in Medicinal Chemistry and Head of the Open Innovation team of Boehringer Ingelheim. This initiative provides well-characterized, high quality pre-clinical tool compounds to interested researchers worldwide through the opnMe.com portal. In addition, he has a strong interest in CNS projects and is project leader from the hit findings phase to the final pre-clinical candidate selection.

Markus Koester is Director of the Department Research Coordination Germany as part of the Discovery Research organization of Boehringer Ingelheim where he currently leads the communication efforts of the open innovation portal of Boehringer Ingelheim, opnMe.com. He has established scientific crowdsourcing as a new open innovation tool to attract externally generated new therapeutic concepts for Boehringer Ingelheim’s preclinical pipeline and was deeply involved in the launch of opnMe.com. Over his professional career Markus has accumulated broad experience in pharmaceutical drug discovery, development and innovation both in research and commercial roles.

Susanne Müller-Knapp is Chief Operating Officer at the SGC Frankfurt and is coordinating several probe programs including the global SGC kinase chemical probe program. She is also Director of Operations of the Chemical Probes Portal, an online platform, providing recommendations for the right choice and use of chemical probes. Susanne has been associated to the SGC in Oxford at first as External Research Manager and then Scientific Coordinator. Later on, she has been the Project Manager of the Epigenetic Probe Project.